PHARM Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.…
Industry Peers
BiotechnologyKey Statistics
About Pharming Group (AMS: PHARM)
›
Pharming Group (AMS: PHARM) is listed on Euronext Amsterdam, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 407 employees.
The shares were at 1.099 EUR on 20 November 2026, down 19.7% over 52 weeks. Its 52-week range is 0.8202 EUR to 1.818 EUR: the price is 39.6% below the high and 33.9% above the low.
At a market capitalisation of 789.53M EUR, it trades at 37.2 times trailing earnings and 33.2 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 11% for PHARM.
Pharming Group reports return on equity of 1.0%, an operating margin of 12.8% and revenue up 20.8% year over year.
It holds more cash than debt, a net cash position of 75.05M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 2.244 EUR is 104.3% above the current price. The next earnings report is expected on 11 March 2027.